Glycocalyx Research Institute Announces Breakthrough Study Linking Microvascular Health to Reduced Cancer Radiation Therapy Side Effects
25 Julio 2024 - 12:16PM
Business Wire
The study included 63 breast cancer patients, 38 prostate cancer
patients, and 39 head and neck cancer patients. It found that the
group with the healthiest microvascularization had no ill side
effects, while those with the least healthy microascularization
experienced the most severe side effects
The Glycocalyx Research Institute is proud to announce
groundbreaking results from a recent study investigating the role
of microvascular health (microscopic capillary vascularization that
comprises 99% of the body’s vascular system) in predicting acute
toxicities from radiation therapy in breast, prostate, and head and
neck cancer patients. The study, published in the International
Journal of Radiation Oncology and conducted in collaboration with
the Fondazione IRCCS Istituto Nazionale dei Tumori and the
University of Verona Hospital Trust, has revealed that healthier
microvascularization significantly reduces the risk of severe
side effects from radiation treatments.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240725218193/en/
The research team utilized the Glycocalyx Research Institute’s
innovative GlycoCheck™ imaging device, developed by the Institute’s
co-founder, Dr. Hans Vink, to assess patients' microvascular health
before starting radiation therapy. This non-invasive microscopic
device captures red blood cells moving through the microvessels and
computes a comprehensive MicroVascular Health Score (MVHS).
"The outcome of this study highlights the critical role of
microvascular health in determining the side effects of radiation
therapy," stated Dr. Hans Vink. "Patients with healthy micro
vessels experienced significantly fewer adverse effects,
underlining the importance of maintaining microvascular
integrity."
The study included 63 breast cancer patients, 38 prostate cancer
patients, and 39 head and neck cancer patients. It found that the
group with the healthiest microvascularization had no ill side
effects, while those with the least healthy microascularization
experienced the most severe side effects.
"These findings support a new approach to cancer treatment,
where improving microvascular health can be a key strategy in
reducing treatment-related side effects," Dr. Vink explained. "Our
GlycoCheck imaging device has proven instrumental in assessing
microvascular health. This study's findings pave the way for using
such non-invasive diagnostics to tailor radiation therapy
treatments more effectively."
Dr. Vink also emphasized the potential of the Institute's
nutritional therapeutic product, ReVasca™, which has been shown in
numerous studies to repair and restore microvascular health. "I am
particularly excited about the implications of these results for
our therapeutic product, ReVasca™. Applying this therapeutic could
potentially enhance patients' resilience to radiation therapy and
reduce associated toxicities," he said. "ReVasca™ offers a
promising solution to achieve this, benefiting patients' overall
health and quality of life during and after therapy."
The Glycocalyx Research Institute remains committed to advancing
the understanding and treatment of microvascular health. This study
marks a significant step forward in the Institute's mission to
improve patient outcomes through innovative research and
therapeutic solutions.
For more information on GlycoCheck™and ReVasca™, please visit
https://www.GlycoCalyx.com
About Glycocalyx Research Institute: The Glycocalyx Research
Institute, founded by Dr. Hans Vink and Robert Long in 2012, is
dedicated to pioneering research and development in microvascular
health. The Institute's mission is to enhance the understanding and
treatment of microvascular diseases, improving patient outcomes
worldwide.
GlycoCheck™ and ReVasca™ are trademarks of the Glycocalyx
Research Institute.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240725218193/en/
Steve DeVore, Glycocalyx Research Institute
devore@glycocalyx.com (385) 335-9023 www.GlycoCalyx.com